CoChat

Efficacy of antidepressants for depression in Alzheimer's disease: systematic review and meta-analysis

Open access
Orgeta, Vasiliki, Tabet, Naji, Nilforooshan, Ramin, Howard, Robert · 2017 · Journal of Alzheimer's Disease

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Depression is common in people with Alzheimer's disease (AD) affecting overall outcomes and decreasing quality of life. Although depression in AD is primarily treated with antidepressants, there are few randomized controlled trials (RCTs) assessing efficacy and results have been conflicting. OBJECTIVES: To systematically review evidence on efficacy of antidepressant treatments for depression in AD. METHODS: Systematic review and meta-analysis of double blind RCTs comparing antidepressants versus placebo for depression in AD. We searched MEDLINE, CINAHL, EMBASE, PsycINFO, the Cochrane Controlled Trials Register and on line national and international registers. Primary outcomes were treatment response and depressive symptoms. Secondary outcomes were cognition, acceptability, and tolerability. Risk of bias was also assessed. RESULTS: Seven studies met inclusion criteria. Three compared sertraline with placebo; one compared both sertraline and mirtazapine to placebo; imipramine, fluoxetine, and clomipramine were evaluated in one study each. In terms of response to treatment (6 studies, 297 patients treated with antidepressants and 223 with placebo), no statistically significant difference between antidepressants and placebo was found (odds ratio (OR) 1.95, 95% CI 0.97-3.92). We found no significant drug-placebo difference for depressive symptoms (5 studies, 311 patients, SMD -0.13; 95% CI -0.49 to 0.24). Overall quality of the evidence was moderate because of methodological limitations in studies and the small number of trials. CONCLUSION: Despite the importance of depression in people with AD, few RCTs are available on efficacy of antidepressants, limiting clear conclusions of their potential role. There is a need for further high quality RCTs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-161247

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig.1 Flow diagram of the review.
Fig.1 Flow diagram of the review.CC BY-NC · PubMed Central
Fig.2 Forest plot of comparison of antidepressants versus placebo: Response to treatment (6–13 weeks).
Fig.2 Forest plot of comparison of antidepressants versus placebo: Response to treatment (6–13 weeks).CC BY-NC · PubMed Central
Fig.3 Forest plot of comparison of antidepressants versus placebo: Mean depression scores (6–13 weeks).
Fig.3 Forest plot of comparison of antidepressants versus placebo: Mean depression scores (6–13 weeks).CC BY-NC · PubMed Central
Fig.4 Forest plot of comparison of antidepressants versus placebo: Cognition MMSE scores (6–13 weeks).
Fig.4 Forest plot of comparison of antidepressants versus placebo: Cognition MMSE scores (6–13 weeks).CC BY-NC · PubMed Central
Fig.5 Forest plot of comparison of antidepressants versus placebo: Acceptability Number of drop-outs (6–13 weeks).
Fig.5 Forest plot of comparison of antidepressants versus placebo: Acceptability Number of drop-outs (6–13 weeks).CC BY-NC · PubMed Central
Fig.6 Forest plot of comparison of antidepressants versus placebo: Tolerability Number of adverse events (6–13 weeks).
Fig.6 Forest plot of comparison of antidepressants versus placebo: Tolerability Number of adverse events (6–13 weeks).CC BY-NC · PubMed Central
Fig.7 Risk of bias graph: review authors’ judgements about each risk of bias item presented as percentages across all included studies.
Fig.7 Risk of bias graph: review authors’ judgements about each risk of bias item presented as percentages across all included studies.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Knapp, 2014, PSSRU Discussion Paper, 2878

Cited by

See all 213

Metadata

Authors
Orgeta, V., Tabet, N., Nilforooshan, R., & Howard, R.
Affiliations
Brighton and Sussex Medical School (GB)
Corresponding author
Orgeta, Vasiliki
Venue
Journal of Alzheimer's Disease
Published
2017-06-05
Volume
58
Issue
3
Pages
725-733
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W2612913686
Cited by
203
References
50
Citations by year
2026: 13 · 2025: 19 · 2024: 29 · 2023: 23 · 2022: 30 · 2021: 30 · 2020: 18 · 2019: 25 · 2018: 15
FWCI
2.41
Type
journal article
Language
en
Open access
Locations
  • Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Sussex Research Online (University of Sussex) (submittedVersion, cc-by-nc)
  • UCL Discovery (University College London) (submittedVersion)
  • Figshare (submittedVersion, cc-by-nc)
Funders
  • Alzheimer's Society
  • National Institute for Health and Care Research
  • University College London
  • University College London Hospitals NHS Foundation Trust
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
Alzheimer's disease, depression
MeSH terms
Alzheimer Disease, Antidepressive Agents, Depressive Disorder, Humans, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.